Many studies in human breast cancer have explored the protective effects of Bcl-2 positivity in luminal breast cancers, i.e., which are positive to Estrogen Receptor alpha (ER) and/or Progesterone Receptor (PR), and have found that Bcl-2 positivity is associated with a better outcome [7, 16–19]. Here, ESR1 is linked to breast carcinoma.